AbCellera Biologics Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Carl L.G. Hansen Ph.D.
- Full Time Employees
- 586
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2215 Yukon Street Vancouver BC Canada V5Y 0A1
- IPO Date
- Dec 11, 2020
- CIK
- 0001703057
- Website
- abcellera.com
- Similar Companies
- Business
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Company News
AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
AbCellera: A Waiting Game With High Uncertainty
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street
Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?
AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know
AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024
Down 57%, Is AbCellera Biologics a Buy on the Dip?
AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
3 Stock Gems Hiding in the Nasdaq
AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Reports Q1 2024 Business Results
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
The 7 Best Penny Stocks to Buy in Q2 2024
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024